Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma

由 van der Horst, Hilma J., Gelderloos, Anne T., Chamuleau, Martine E. D., Breij, Esther C. W., Zweegman, Sonja, Nijhof, Inger S., Overdijk, Marije B., Mutis, Tuna
發表在 Blood Adv (2021)

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy

由 Roit, Fabio Da, Engelberts, Patrick J., Taylor, Ronald P., Breij, Esther C.W., Gritti, Giuseppe, Rambaldi, Alessandro, Introna, Martino, Parren, Paul W.H.I., Beurskens, Frank J., Golay, Josée
發表在 Haematologica (2015)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

由 Overdijk, Marije B, Verploegen, Sandra, Bögels, Marijn, van Egmond, Marjolein, van Bueren, Jeroen J Lammerts, Mutis, Tuna, Groen, Richard WJ, Breij, Esther, Martens, Anton CM, Bleeker, Wim K, Parren, Paul WHI
發表在 MAbs (2015)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

由 van der Horst, Hilma J., Oostindie, Simone C., Cillessen, Saskia. A. G. M., Gelderloos, Anne T., Overdijk, Marije B., Nijhof, Inger. S., Zweegman, Sonja, Chamuleau, Martine E. D., Breij, Esther C. W., Mutis, Tuna
發表在 Hemasphere (2020)

Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer

由 Koopman, Louise A., Terp, Mikkel G., Zom, Gijs G., Janmaat, Maarten L., Jacobsen, Kirstine, Gresnigt-van den Heuvel, Elke, Brandhorst, Marcel, Forssmann, Ulf, de Bree, Freddy, Pencheva, Nora, Lingnau, Andreas, Zipeto, Maria A., Parren, Paul W.H.I, Breij, Esther C.W., Ditzel, Henrik J.
發表在 JCI Insight (2019)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

由 van der Horst, Hilma J., de Jonge, A. Vera, Hiemstra, Ida H., Gelderloos, Anne T., Berry, Daniella R. A. I., Hijmering, Nathalie J., van Essen, Hendrik F., de Jong, Daphne, Chamuleau, Martine E. D., Zweegman, Sonja, Breij, Esther C. W., Roemer, Margaretha G. M., Mutis, Tuna
發表在 Blood Cancer J (2021)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

由 Engelberts, Patrick J., Hiemstra, Ida H., de Jong, Bart, Schuurhuis, Danita H., Meesters, Joyce, Beltran Hernandez, Irati, Oostindie, Simone C., Neijssen, Joost, van den Brink, Edward N., Horbach, G. Jean, Verploegen, Sandra, Labrijn, Aran F., Salcedo, Theodora, Schuurman, Janine, Parren, Paul W.H.I, Breij, Esther C.W.
發表在 EBioMedicine (2020)

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

由 Oostindie, Simone C., van der Horst, Hilma J., Lindorfer, Margaret A., Cook, Erika M., Tupitza, Jillian C., Zent, Clive S., Burack, Richard, VanDerMeid, Karl R., Strumane, Kristin, Chamuleau, Martine E. D., Mutis, Tuna, de Jong, Rob N., Schuurman, Janine, Breij, Esther C. W., Beurskens, Frank J., Parren, Paul W. H. I., Taylor, Ronald P.
發表在 Haematologica (2019)

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies

由 Oostindie, Simone C., van der Horst, Hilma J., Kil, Laurens P., Strumane, Kristin, Overdijk, Marije B., van den Brink, Edward N., van den Brakel, Jeroen H. N., Rademaker, Hendrik J., van Kessel, Berris, van den Noort, Juliette, Chamuleau, Martine E. D., Mutis, Tuna, Lindorfer, Margaret A., Taylor, Ronald P., Schuurman, Janine, Parren, Paul W. H. I., Beurskens, Frank J., Breij, Esther C. W.
發表在 Blood Cancer J (2020)